[Treatment of hypereosinophilia].
Therapeutic management of blood hypereosinophilia depends on its underlying cause. The cause may be clearly established (parasitic infestation) or more hypothetical (systemic disease). Blood eosinophils often return to normal levels after treatment of either the cause or the associated eosinophilic disease. A targeted approach is more difficult when the cause is unknown (unexplained chronic hypereosinophilia). Various conventional treatments (corticosteroids, hydroxyurea, interferon) have been somewhat effective. The identification of new cellular and molecular markers with diagnostic and pathophysiologic significance makes more rational approaches possible.
Charlanne
Hilaire
H
Service de médecine interne, Hôpital Claude Huriez, Lille. hilaire.charlanne@wanadoo.fr
Prin
Lionel
L
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000008:administration & dosage / Q000627:therapeutic use; D001549:Benzamides; D002908:Chronic Disease; D003524:Cyclosporins / Q000008:administration & dosage / Q000627:therapeutic use; D004351:Drug Resistance; D004802:Eosinophilia / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000469:parasitology; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000627:therapeutic use; D000068877:Imatinib Mesylate; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use; D009196:Myeloproliferative Disorders / Q000150:complications; D010272:Parasitic Diseases / Q000150:complications; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use; D012008:Recurrence; D013997:Time Factors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D001549:Benzamides; D003524:Cyclosporins; D005938:Glucocorticoids; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D016898:Interferon-alpha; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000074323:Alemtuzumab; D000068877:Imatinib Mesylate; C434107:mepolizumab; D006918:Hydroxyurea